Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Nomura Elevates WUXI BIO (02269.HK) TP to $50.54 as Preliminary 2025 Results Beat
Recommend 9 Positive 10 Negative 7 |
||||
|
||||
|
WUXI BIO (02269.HK) announced a positive profit alert projecting its 2025 revenue to grow by 16.7% YoY to RMB21.8 billion, slightly above the market consensus of RMB21.5 billion, according to Nomura's research report. Gross margin is expected to improve by 5 ppts YoY to 46%, also exceeding the market expectation of 43%. Net profit/ net profit attributable to shareholders are predicted to increase by 45.3%/ 46.3% YoY to RMB5.7 billion/ RMB4.9 billion, ahead of market estimations of RMB4.8 billion/ RMB4.4 billion, respectively. The broker believed that its subsidiary WUXI XDC (02268.HK) is a significant contributor to revenue growth. Excluding the contribution from WUXI XDC, 2H25 revenue is expected to grow by 12% YoY to RMB9.9 billion, accelerating from 9% in 1H25. Therefore, Nomura elevated its target price from $37.36 to $50.54, with rating kept at Buy. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
